<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations at codon 641 of EZH2 are recurrent in germinal center B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and the most common variants lead to altered EZH2 enzymatic activity and enhanced tri-methylation of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 at lysine 27, a repressive chromatin modification </plain></SENT>
<SENT sid="1" pm="."><plain>As an initial step toward screening patients for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> genotype-directed therapy, we developed a screening assay for EZH2 codon 641 mutations amenable for testing formalin-fixed clinical specimens, based on the sensitive SNaPshot single nucleotide extension technology </plain></SENT>
<SENT sid="2" pm="."><plain>We detected EZH2 mutations in 12/55 (22%) follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FL), 5/35 (14%) diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with a germinal center immunophenotype (<z:e sem="disease" ids="C1333295" disease_type="Neoplastic Process" abbrv="">GCB-DLBCL</z:e>), and 2/11 (18%) high grade B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with concurrent rearrangements of BCL2 and MYC </plain></SENT>
<SENT sid="3" pm="."><plain>No EZH2 mutations were detected in cases of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0/23) </plain></SENT>
<SENT sid="4" pm="."><plain>EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p&lt;0.05) and <z:e sem="disease" ids="C1333295" disease_type="Neoplastic Process" abbrv="">GCB-DLBCL</z:e> groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p&lt;0.04), and across <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types excluding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (27% of BCL2-R cases versus 3% of BCL2-WT cases, p&lt;0.003) </plain></SENT>
<SENT sid="5" pm="."><plain>We confirmed gain-of-function activity for <z:hpo ids='HP_0000001'>all</z:hpo> previously reported EZH2 codon 641 mutation variants </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings suggest that EZH2 mutations constitute an additional genetic "hit" in many BCL2-rearranged germinal center B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Our work may be helpful in the selection of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients for future trials of pharmacologic agents targeting EZH2 and EZH2-regulated pathways </plain></SENT>
</text></document>